[<sup>18</sup>F]tetrafluoroborate-PET/CT enables sensitive tumor and metastasis in vivo imaging in a sodium iodide symporter-expressing tumor model by DIocou, S. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/s41598-017-01044-4
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
DIocou, S., Volpe, A., Jauregui-Osoro, M., Boudjemeline, M., Chuamsaamarkkee, K., Man, F., ... Fruhwirth, G.
O. (2017). [18F]tetrafluoroborate-PET/CT enables sensitive tumor and metastasis in vivo imaging in a sodium
iodide symporter-expressing tumor model. Scientific Reports, 7(1), [946]. https://doi.org/10.1038/s41598-017-
01044-4
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
1Scientific RepoRts | 7: 946  | DOI:10.1038/s41598-017-01044-4
www.nature.com/scientificreports
[18F]tetrafluoroborate-PET/
CT enables sensitive tumor 
and metastasis in vivo imaging 
in a sodium iodide symporter-
expressing tumor model
S. Diocou1, A. Volpe1, M. Jauregui-Osoro1, M. Boudjemeline1, K. Chuamsaamarkkee1,  
F. Man  1, P. J. Blower1, T. Ng2,3, G. E. D. Mullen1 & G. O. Fruhwirth  1
Cancer cell metastasis is responsible for most cancer deaths. Non-invasive in vivo cancer cell tracking 
in spontaneously metastasizing tumor models still poses a challenge requiring highest sensitivity and 
excellent contrast. The goal of this study was to evaluate if the recently introduced PET radiotracer [18F]
tetrafluoroborate ([18F]BF4−) is useful for sensitive and specific metastasis detection in an orthotopic 
xenograft breast cancer model expressing the human sodium iodide symporter (NIS) as a reporter. 
In vivo imaging was complemented by ex vivo fluorescence microscopy and γ-counting of harvested 
tissues. Radionuclide imaging with [18F]BF4− (PET/CT) was compared to the conventional tracer [123I]
iodide (sequential SPECT/CT). We found that [18F]BF4− was superior due to better pharmacokinetics, i.e. 
faster tumor uptake and faster and more complete clearance from circulation. [18F]BF4−-PET was also 
highly specific as in all detected tissues cancer cell presence was confirmed microscopically. Undetected 
comparable tissues were similarly found to be free of metastasis. Metastasis detection by routine 
metabolic imaging with [18F]FDG-PET failed due to low standard uptake values and low contrast caused 
by adjacent metabolically active organs in this model. [18F]BF4−-PET combined with NIS expressing 
disease models is particularly useful whenever preclinical in vivo cell tracking is of interest.
Most cancer-related deaths are a result of metastatic disease1. Reliable imaging of cancer metastases in model sys-
tems is difficult to achieve and may require a multi-modal imaging approach. In vivo cell-tracking methods can be 
used as a tool to preclinically monitor the presence, distribution, quantity, and viability of malignant cells in pri-
mary tumors and distant metastases, noninvasively, longitudinally and in real time in the body. Small animal radi-
onuclide imaging techniques such as positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) offer good depth penetration and the possibility of absolute quantification2 with resolution 
of <1 mm3, 4. Bioluminescence imaging is less expensive but is affected by differential light absorption and poor 
depth penetration, precluding full 3D quantification5. Fluorescence whole-body imaging is less sensitive as com-
pared to bioluminescence technology5, but has the advantage of enabling fluorescence microscopy-afforded his-
tology. Therefore, radionuclide and fluorescence imaging complement one another, ranging from the whole-body 
level to the (sub-)cellular scale. PET and SPECT are well-suited for tracking cells in preclinical models, as the 
imaging agents are versatile and can be introduced conveniently through direct cell labeling, tracer uptake by 
endogenous transport proteins, tracer binding through specific high-affinity interactions with surface molecules, 
or by using reporter gene strategies.
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The sodium/iodide symporter (NIS) has a long imaging history because there is a variety of γ-camera/SPECT 
radiotracers including [123I]iodide, [125I]iodide and 99mTcO4−, all of which are widely available at comparatively 
low cost without the need for specialist radiochemistry facilities. NIS has been the basis of molecular imaging and 
radionuclide therapy of thyroid disease for many years6, 7. It is naturally highly expressed in the thyroid and, at 
lower levels, in only a limited number of extra-thyroidal tissues (i.e. salivary, lachrymal and lactating mammary 
glands, and the stomach), thereby enabling good contrast imaging in other body regions. As a symporter, its 
anion import is coupled to sodium import, which is fuelled by the electrochemical gradient of sodium ions across 
cell membranes7. Therefore, NIS reports on viable cells only. NIS is highly homologous between human, rat and 
mouse7 and has so far not been reported to exert any toxicity upon ectopic expression in non-thyroidal cells. It 
has also not been reported to trigger host immune responses (in human, mouse and rat), which can be a concern 
when foreign reporters are used in the context of fully immunocompetent animals. The combination of ectopic 
NIS expression with NIS radiotracers has been used to assess promoter activity8–10, gene expression11–16 and most 
recently to monitor cells in therapeutic settings ([131I]iodide and 188ReO4−)17–20.
The quest to image ever smaller cell populations in vivo, for example in gene and cell therapy but also cancer 
metastases research, renders in vivo imaging sensitivity and resolution in such whole-body cell tracking appli-
cations paramount. Generally, PET has been considered to be superior to SPECT in this respect, particularly in 
large animals and humans. Accordingly, the PET isotope [124I]iodide has been introduced for PET imaging in 
thyroid disease and NIS reporter gene imaging21. However, 124I undergoes a complex decay scheme22 with a low 
abundance of positrons (23%) and abundant high-energy γ photons that can lead to poor PET image quality. Its 
long half-life, low positron yield, high positron energy and abundant high energy γ emissions result in a high 
radiation dose and less-than-ideal imaging properties (as compared to other PET isotopes such as 18F).
Pharmacokinetics and radiation emission properties affect the choice of radionuclides for NIS reporter gene 
imaging. Use of radioiodine in the context of NIS reporter gene imaging with PET or SPECT is complicated 
by the fact that, as well as being a substrate of NIS, iodide is a substrate of the peroxidase machinery of thyroid 
hormone synthesis, leading to metabolic trapping. This trapping mechanism is an advantage in imaging normal 
thyroid function or response to thyroid ablation, but complicates reporter gene imaging because it increases 
thyroid uptake, making the tracer less available for uptake in the non-thyroidal target cells, which do not have 
this additional metabolic trapping machinery. In contrast, pertechnetate is a ‘pure’ NIS substrate without meta-
bolic complications and therefore has reduced uptake in normal thyroid. A positron-emitting functional analog 
of 99mTcO4− would bring the advantages of PET, including improved resolution, sensitivity, quantification and 
dynamic imaging, without the undesirable metabolic complications associated with [124I]iodide. We recently 
reported that [18F]BF4− meets this need. It has the advantages of the functional analogy to 99mTcO4− 23–25, while 
incorporating the radionuclide 18F, which is readily available and has excellent PET imaging characteristics.
Results
Specific [18F]BF4− uptake in tumor cells expressing the NIS-TagRFP reporter. We chose the 
established breast adenocarcinoma cell line MTLn3E as the basis for the tumor models in this study. MTLn3E 
cells were engineered to stably and uniformly express (i) the truncated chemokine CXC receptor 4 to render the 
cells more metastatic26, 27 (3E.Δ cells), and (ii) the radionuclide-fluorescence fusion reporter gene NIS-TagRFP 
(3E.Δ-NIS cells)28. First, we determined the ability of these cell lines to take up the NIS PET radiotracer [18F]
BF4−. As expected, 3E.Δ-NIS cells took up [18F]BF4− significantly better than 3E.Δ cells, which lack the NIS-
TagRFP reporter gene and any detectable endogenous NIS expression (59-fold difference; P = 0.0001; Fig. 1). 
3E.Δ-NIS cells showed about 5-times higher [18F]BF4− uptake than the TSH-treated rat thyroid cells (FRTL-5), 
which served as a reference. Pre-incubation of 3E.Δ-NIS cells with the competitive NIS substrate ClO4− (1 μM) 
Figure 1. The exogenously expressed NIS reporter is functional in highly invasive breast carcinoma cells. [18F]
BF4− uptake was measured in vitro in highly metastatic cell lines either stably expressing the reporter gene NIS-
TagRFP (3E.Δ-NIS, black bars) or not (3E.Δ). Uptake was compared to that of FRLT-5 thyroid cells, which 
endogenously express NIS if grown in the presence of TSH (see Materials and Methods). Perchlorate blockade 
was used to demonstrate uptake specificity. Error bars represent SD of three independent experiments, each in 
triplicate.
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led to a 98% reduction (P = 0.0001) of [18F]BF4− uptake thereby demonstrating that the uptake was NIS-specific 
(Fig. 1). We then determined the detection sensitivity of our nanoPET/CT in vivo imaging system by embedding 
NIS-positive 3E.Δ-NIS cells within small cell pellets of NIS-negative 3E.Δ cells. This revealed a detection limit of 
2,000 3E.Δ-NIS cells within a volume of 500,000 cells (see Supplementary Fig. S1).
Specific [18F]BF4− uptake in tumors expressing the NIS-TagRFP reporter in vivo. Subsequently, 
we established orthotopic tumor models using both 3E.Δ and 3E.Δ-NIS cell lines via mammary fat pad injec-
tions into young adult immunocompromised SCID/Beige mice. Tumors were grown to volumes of ~55 mm3 
(Supplementary Fig. S2A), which was at a sufficiently early progression stage that metastasis on-set had not 
yet taken place in this model (as confirmed by animal dissection under fluorescence light). Animals bearing 
3E.Δ-NIS tumors showed [18F]BF4− uptake in the primary tumors and organs endogenously expressing NIS 
(thyroid and salivary glands, stomach, lachrymal glands; Fig. 2a/b) as determined by PET/CT imaging. [18F]
BF4− was also excreted renally as demonstrated by radiotracer amounts residing in the kidneys and the bladder 
with the majority in the latter at this imaging time point. NIS-specificity of [18F]BF4− uptake was demonstrated 
in vivo by the following observations: first, there was no significant tracer uptake in non-NIS expressing primary 
tumors (3E.Δ) (Fig. 2a) and second, administration of ClO4− before radiotracer administration in a repeat scan 
of 3E.Δ-NIS tumor-bearing animals abolished uptake in primary tumors and all endogenous NIS-expressing 
organs (Fig. 2b). Subsequent to animal euthanasia, primary tumors were harvested, sectioned and subjected to 
confocal fluorescence microscopy, which revealed the presence of green fluorescent tumor cells in both tumor 
groups (3E.Δ and 3E.Δ-NIS expressing Δ34-CXCR4-eGFP). Importantly, it also revealed expression and plasma 
membrane localization (required for function) of the reporter gene NIS-TagRFP in primary tumors grown from 
3E.Δ-NIS cells only (Fig. 2c). The chosen sequential imaging approach in which one or more tracers are used 
in the same animal one after the other, after a suitable period for excretion and decay, relies on the assumption 
that the first tracer does not alter the biodistribution of the second. This assumption is experimentally validated 
(Fig. S3).
Comparison of dynamic in vivo [18F]BF4−-PET with [123I]iodide-SPECT imaging. For this experi-
ment primary 3E.Δ-NIS tumors were grown to sizes of ~350 mm3 (see Supplementary Fig. S2B) before imaging 
the animals by PET/CT (with [18F]BF4− as the radiotracer) or by SPECT/CT (with [123I]iodide). PET images were 
acquired continuously (see Materials and Methods) while SPECT required a series of static images (12 min each). 
To render PET and SPECT scans comparable, we re-binned dynamic PET scans to the individual times required 
for short SPECT scans. Representative in vivo images are shown in Fig. 3a ([18F]BF4−-PET) and Fig. 3b ([123I]
iodide-SPECT), respectively. The corresponding imaging experiments were also used to determine time-activity 
curves (TAC) for both tracers in the primary tumors and a variety of organs of interest including the thyroid, 
salivary glands, stomach and the left ventricle of the heart (as a surrogate for the blood pool). The TACs were 
determined by analyzing the respective VOIs from both [18F]BF4−-PET and [123I]iodide-SPECT scans (Fig. 4). 
[18F]BF4− accumulated in the primary tumor and was readily detectable there (Fig. 3a) by 12 min after tracer 
administration (5.1 ± 0.3%ID; SUV = 3.1 ± 0.2; Fig. 4a). In contrast, due to the relatively high background/blood 
pool activity (see below), the [123I]iodide-SPECT images did not show a well-defined primary tumor 12 min 
after tracer administration (Fig. 3b). At that time point [123I]iodide uptake was 3.6 ± 0.7%ID (SUV = 2.2 ± 0.5) 
and also significantly lower than with [18F]BF4− (P = 0.0290; Fig. 4b). To fully identify the whole primary tumor 
in [123I]iodide-SPECT images at least 36 min of post-administration imaging was required (Fig. 3b). We imaged 
each animal for a total period of 2 h after which the tumor uptake was 24.1 ± 3.3%ID (SUV = 14.8 ± 2.0) for [18F]
BF4− and 20.1 ± 2.8%ID (SUV = 12.4 ± 1.7) for [123I]iodide, respectively (Fig. 4a/b).
As expected, [18F]BF4− accumulated also in organs endogenously expressing NIS. In the thyroid, its accumu-
lation peaked after around 24 min at 2.6 ± 1.0%ID (SUV = 7.0 ± 2.5; Fig. 4a) before gradually decreasing again. 
In contrast, [123I]iodide continued to accumulate in the thyroid over the whole observation time. While its uptake 
levels were 1.6 ± 0.5%ID (SUV = 4.1 ± 1.2) at 12 min, they increased to 5.2 ± 0.9%ID (SUV = 13.3 ± 2.4) after 2 h 
(Fig. 4b). This demonstrated clearly different uptake behaviors of radioiodide and [18F]BF4−, consistent with the 
fact that [123I]iodide accumulates due to uptake and subsequent organification in the thyroid tissues, while [18F]
BF4− cannot be organified.
Importantly, clearance from the blood also differed between the two NIS radiotracers. The %ID values for 
the left ventricle of the heart were obtained directly from images and served as a surrogate for the blood pool. 
Interestingly, [18F]BF4− cleared faster from circulation than [123I]iodide: 12 min after [18F]BF4− administra-
tion we found it at levels of 0.10 ± 0.01%ID (SUV = 0.32 ± 0.05) while we found [123I]iodide at higher levels of 
0.18 ± 0.07%ID (SUV = 1.28 ± 0.54; P = 0.0383; Fig. 4). At later time points both values decreased but in the case 
of [123I]iodide a plateau was reached (time > 80 min: 0.05 ± 0.01%ID; SUV = 0.33 ± 0.07), while for [18F]BF4− the 
values approximated zero (%ID < 0.01; SUV ≤ 0.01; Fig. 4c). The differences between the two NIS radiotracers 
were significant (P < 0.05) for all time points ≥36 min.
An important consequence of the faster and more complete clearance of [18F]BF4− paired with its faster tumor 
uptake is that its tumor-to-blood ratio (left ventricle as a surrogate) is higher as compared to [123I]iodide. We 
found it to be 51 and 3600 at 12 min and 36 min after [18F]BF4− administration, which was 2.6- and 30.8-fold 
higher than for [123I]iodide (tumor-to-blood ratios of 20 and 117 at these times points, respectively). Because 
of [123I]iodide not being completely cleared from the blood stream or, potentially, organified 123I being secreted 
back into the blood stream, tumor-to-blood ratios were consistently lower at all later time points (18- to 25-fold).
Subsequent to in vivo imaging, animals were euthanized and organs harvested to determine the radioactivity 
taken up into the various tissues ex vivo by γ-counting. The average tumor SUV was higher in the case of [18F]
BF4− (6.4 ± 1.7; Fig. 4d) than in the case of [123I]iodide (2.9 ± 2.0; P = 0.0372). In contrast, the SUV values for the 
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Figure 2. Primary xenograft tumors established from NIS-expressing breast cancer cells can specifically be 
imaged with [18F]BF4−-PET. (a) Tumors were established from 3E.Δ cells stably expressing constitutively active 
truncated CXCR4-GFP but not NIS-TagRFP (left) or from 3E.Δ-NIS cells stably expressing both truncated 
CXCR4-GFP and NIS-TagRFP (right). Tumors were imaged by [18F]BF4−-PET when sizes of ~55 mm3 were 
reached (see Supplementary Fig. S2A). As expected, no tumor signals were seen by PET/CT in the case of 
3E.Δ tumors. For 3E.Δ-NIS tumors, PET/CT signals were very pronounced. A representative example is 
shown. (b) NIS specificity was tested in the same animals 48 h later by pre-treatment with perchlorate before 
repeat [18F]BF4−-PET imaging. All [18F]BF4−-PET signals except in the organs of the [18F]BF4− excretion 
pathway, i.e. kidneys and bladder, vanished in perchlorate-treated animals (as compared to the earlier image 
of the same animal as in (a)), thereby proving successful NIS blockade and thus NIS specificity. All images 
are maximum intensity projections overlaid on CT. Abbreviations are: bladder (B), kidney (K), stomach (S), 
thyroid and salivary glands (Th + SG), and primary tumor (T). (c) Typical confocal micrographs of sections 
cut from primary tumors after γ-counting confirming expression of truncated CXCR4-GFP in both tumors but 
expression of NIS-TagRFP only in the 3E.Δ-NIS tumor (bottom row). Scale bars are 25 μm.
www.nature.com/scientificreports/
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thyroid were lower for [18F]BF4− (8.1 ± 2.1) than for [123I]iodide (20.0 ± 7.1; P = 0.0183) showing a similar trend 
as the data on thyroid uptake obtained by imaging (Fig. 4e).
Small metastases of NIS-expressing tumors were detected by [18F]BF4−-PET but not by [18F]
FDG-PET. Next, we determined whether [18F]BF4− would be a suitable PET radiotracer for metastasis track-
ing in NIS-expressing tumors. We established 3E.Δ-NIS tumors and let them progress until distant metastasis 
was a consistent feature (19 days; as determined by preliminary experiments based on animal dissection under 
fluorescence illumination). A representative [18F]BF4−-PET/CT image demonstrates radiotracer uptake in the 
primary tumor and various metastatic lesions (Fig. 5a). All regions of interest that were PET-positive were har-
vested. As lymph node metastasis was a predominant feature in this model, we also harvested lymph nodes 
with no PET-detectable uptake as controls, i.e. the lymph nodes contralateral to the affected ones from the same 
animals. Confocal fluorescence microscopy confirmed that all tissues with detectable radiotracer uptake in the 
[18F]BF4−-PET/CT images were also positive for 3E.Δ-NIS cells (N = 8 animals; see Fig. 5b–e for a representa-
tive example). Conversely, no 3E.Δ-NIS cells were detected in contralateral lymph nodes that did not show any 
uptake in the corresponding [18F]BF4−-PET images (Fig. 5f). The average SUV values in the primary tumors and 
all metastases were greater than one (Fig. 5g). For example, metastasis-containing axillary and inguinal lymph 
nodes had average SUV values of 7.5 ± 2.6 (N = 7) and 9.6 ± 6.0 (N = 8), which were significantly higher than for 
Figure 3. Comparative in vivo NIS imaging indicates differences between the PET tracer [18F]BF4− and 
the SPECT tracer [123I]iodide. Tumors were established as in Fig. 2 but grown to sizes of ~350 mm3 (see 
Supplementary Fig. S2B) before being imaged by either [18F]BF4−-PET (a) or [123I]iodide-SPECT (b). Dynamic 
PET data were binned into time intervals comparable to sequential SPECT images (see Materials and Methods). 
Al images are maximum intensity projections overlaid on CT. Abbreviations are: bladder (B), heart (H), kidney 
(K), stomach (S), thyroid and salivary glands (Th + SG), and primary tumor (T). Representative images of 
cohorts of N = 3 are shown.
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unaffected lymph nodes (1.1 ± 0.63; P < 0.0001; N = 17). Importantly, all [18F]BF4−-PET-negative lymph nodes 
had average SUV values of ~1 as was the case for other non-cancerous tissues lacking endogenous NIS expression. 
Peritoneal metastases were not as frequent (20–30% of mice) as compared to inguinal and axillary lymph node 
metastases (100% and 80–90% of mice, respectively) and were also smaller. Peritoneal metastases showed the low-
est SUV values of all cancerous tissues (2.1 ± 0.8; N = 3) but were still significantly different from metastasis-free 
tissues (P = 0.0386 as compared to lymph nodes and P = 0.0003 as compared to muscle); we suspect this was due 
Figure 4. Quantitative analysis of in vivo NIS imaging and ex vivo biodistribution data reveals differences 
in pharmacokinetics between the PET tracer [18F]BF4− and the SPECT tracer [123I]iodide. (a/b) Image data 
analysis of (a) dynamic [18F]BF4−-PET and (b) sequential [123I]iodide-SPECT experiments was performed as 
described in Materials and Methods. Cumulative data of organs expressing exogenous human NIS (primary 
tumor, red) and expressing endogenous NIS (thyroid, green; salivary glands, black; stomach, grey) are shown 
for each tracer. A heart volume comprising of the left ventricle was used as a surrogate for the blood pool (blue). 
Tracer batches were identical for all animals and experiments performed on the same day (N = 3 animals for 
each tracer). (c) A more detailed view of the radioactivity time course in the left ventricle (surrogate for the 
blood pool in vivo). It demonstrates the faster and more complete clearance of [18F]BF4− as compared to [123I]
iodide. (d/e) Ex vivo radioactivity analysis by γ-counting of harvested tissues was performed subsequent to 
imaging. Cumulative SUV data of all experimental animals of the [18F]BF4− (d) and [123I]iodide (e) cohorts 
(N = 5 each). Abbreviations are (from left to right): primary tumors (T), heart (H), blood (BL), muscle (Mu), 
thyroid (Th), stomach (S), and salivary glands (SG). Error bars in all panels represent SD.
www.nature.com/scientificreports/
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Figure 5. Combination of a NIS-expressing tumor model with [18F]BF4−-PET enables reliable and sensitive 
metastasis detection. (a) Representative maximum intensity projection image (overlaid on CT) of a [18F]
BF4−-PET/CT scan of an animal growing a primary tumor established from 3E.Δ-NIS cells. Abbreviations are: 
bladder (B), lachrymal glands (L), stomach (S; dotted), thyroid and salivary glands (Th + SG), and primary 
tumor (T). Full arrows point to metastatic sites and include the following objects (dashed): left inguinal LN, 
liver metastasis, left axillary LN. Dotted arrow points to the site of the right axillary LN (no PET signal) and 
was later confirmed to be metastasis-free (see f). (b–f) Positivity/negativity for metastasis was determined from 
the PET/CT scans and tissues were subsequently harvested, γ-counted and sectioned; confocal microscopy 
confirmed the PET-based classifications in all cases. Confocal fluorescence microscopy revealed cancer cell 
presence by virtue of the fluorescence signals of NIS-TagRFP (top) and truncated CXCR4-GFP (middle). 
Data show the expected plasma membrane localization of both fusion proteins, thereby identifying cancer 
cells, and that signals belong to intact cells (membrane signals circumscribe Hoechst33342-stained cell nuclei 
(bottom)). Micrographs shown belong to the representative animal from (a) and represent (b) the primary 
tumor, (c) metastasis in the inguinal LN, (d) metastasis in the liver, (e) metastasis in the axillary LN, and 
(f) the contralateral axillary LN, which was not affected by metastasis (no signals in the [18F]BF4−-PET and 
fluorescence microscopy data). Scale bars are 25 μm. (g) [18F]BF4− biodistribution data expressed as SUV as 
determined by γ-counting post tissue harvesting. Abbreviations are (from left to right): primary tumors (T), 
axillary lymph nodes (cancer cell-positive; ALN), inguinal lymph nodes (cancer cell-positive; ILN), metastasis-
free lymph nodes (-veLN), liver metastases (LM), peritoneal metastases (PM), heart (H), blood (BL), muscle 
(Mu), bone (whole femur; Bo), thyroid and salivary glands combined (Th + SG), and stomach (S). Shown are 
pooled data of 3E.Δ-NIS tumor (N = 8, right of dotted line) and 3E.Δ tumor animals (NIS-negative tumors, 
N = 6). Error bars represent SEM. Lower case letters in brackets relate the figure panels (b–f) to the columns in 
which they were quantified together with equivalent tissues from other animals.
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to these metastases being inseparable by dissection from mesenteric tissues thus, likely resulting in an overestima-
tion of their weights and a consequential underestimation of their SUV values. It is also noteworthy, that tumors 
established from 3E.Δ cells had very low SUV values (0.11 ± 0.06; N = 6), which were significantly different 
from those of 3E.Δ-NIS tumors (N = 8; P = 0.0004) (Fig. 5g). This not only demonstrated the performance of 
the reporter gene per se, but also showed that the enhanced permeability and retention effect plays no role in this 
experimental setting.
To compare NIS-afforded metastasis tracking by [18F]BF4−-PET with the performance of [18F]FDG for the 
same purpose29, mice with 3E.Δ-NIS tumors were first imaged by [18F]BF4−-PET/CT (day 17) and, after com-
plete 18F decay (1.3·10−6% residual 18F radioactivity after 48 h), with [18F]FDG-PET/CT (day 19). [18F]BF4−-PET 
images (Fig. 6a, left) showed radiotracer uptake in the primary tumors and axillary and inguinal lymph nodes, all 
of which were later confirmed ex vivo to contain metastases using confocal fluorescence microscopy. In contrast, 
[18F]FDG-PET imaging (Fig. 6a, left) allowed the image-based detection of primary tumors but not metastases 
(Fig. 6a, right). Subsequent to [18F]FDG-PET imaging, the animals were euthanized and tissues harvested for ex 
vivo γ-counting. Average SUV values of primary tumors were relatively low 1.1 ± 0.10 (N = 8 animals) but signifi-
cantly higher than the SUV values for blood (0.41 ± 0.35; P < 0.0001) or muscle (0.18 ± 0.12; P < 0.0001). Average 
SUV values for metastasis-positive axillary (0.82 ± 0.04) or inguinal (0.86 ± 0.10) lymph nodes were small but 
higher than SUV values of metastasis-free lymph nodes (0.33 ± 0.14; P < 0.0001). However, smaller metastases 
such as those in the liver (SUV 0.31 ± 0.16) and the peritoneum (SUV 0.39 ± 0.21) were indistinguishable from 
metastasis-free lymph nodes (P = 0.8208 and P = 0.5708, respectively) also by ex vivo γ-counting. Generally, this 
was in marked contrast to the [18F]BF4−-PET data (Fig. 5g) where metastasis-positive lymph nodes differed sig-
nificantly in their SUV values (6.5- to 8.5-fold increase) from metastasis-free lymph nodes, indicating not only 
better sensitivity but also better dynamic range for [18F]BF4−-PET as compared to [18F]FDG-PET in this model.
Discussion
Cell tracking is a task that involves differentiating the cells of interest (e.g. cancer cells) from all other cells 
of the body in space and over an extended period of time, which requires excellent contrast. Some intrinsic 
properties of cancer cells, for example their elevated metabolic activity can be exploited to generate contrast 
(e.g. by using FDG). In principle, the sensitivity of pre-clinical radionuclide imaging-afforded cell tracking 
is dependent on multiple parameters. These include high expression levels of the tracer target in the cells of 
interest, low target abundance in other host tissues, adequate tracer affinity, uptake and retention, radionuclide 
properties, and the chosen imaging technology. We have previously demonstrated the utility of a NIS-based 
radionuclide-fluorescence imaging strategy for in vivo metastasis tracking and therapeutic studies in a breast can-
cer xenograft mode28. In this previous work we used 99mTcO4− as a radiotracer for SPECT imaging as radiotracers 
for PET imaging were either a scarce resource at the time or showed sub-optimal properties (e.g. [124I]iodide22). 
Here, we evaluated our recently introduced PET tracer [18F]BF4− for in vivo metastasis imaging and compared 
its metastasis detection capability to metabolic PET imaging afforded by [18F]FDG in the same NIS-expressing 
tumor model.
For sensitive imaging, the pharmacokinetics of a radiotracer can have a decisive impact on the imaging/
detection performance. Hence, we were interested in a pharmacokinetic comparison of tetrafluoroborate- and 
iodide-based radiotracers. Our comparison of [18F]BF4− with [123I]iodide showed that several pharmacokinetic 
features render [18F]BF4− superior to radioiodide for sensitive imaging in NIS-reporter gene expressing cell track-
ing applications:
Firstly, the absolute thyroid uptake is greater for [123I]iodide; thyroid is the major sink for circulating [123I]
iodide, which is metabolically trapped by conversion into thyroid hormones once transported into the thyroid7. 
In contrast, [18F]BF4− is not metabolically trapped in the thyroid. Consequently, [18F]BF4− is more available than 
radioiodide for uptake into other NIS expressing tissues (this may also account for the higher stomach uptake of 
[18F]BF4−; see Fig. 4d/e).
Secondly, NIS reporter gene-expressing cancerous tissues lack the metabolic entrapment features of the thy-
roid. As a consequence, the advantage that radioiodide has over [18F]BF4− for thyroid imaging is irrelevant for NIS 
reporter gene imaging30. We also found that tetrafluoroborate is taken up by human non-thyroidal NIS-expressing 
cells with higher affinity (as reflected in lower IC50) than iodide as demonstrated in a [99mTc]pertechnetate com-
petition experiment (5.6-times smaller IC50; see Supplementary Fig. S4). Both higher availability and better cel-
lular uptake contribute to a higher absolute uptake of [18F]BF4− as compared to [123I]iodide (see Fig. 4d/e) in 
non-thyroidal NIS-expressing tissues. It is noteworthy that we cannot completely rule out that there is a difference 
in relative affinity of iodide and BF4− between human NIS (ectopically expressed by the reporter gene-expressing 
tumor cells) and mouse NIS (expressed endogenously), which could contribute, at least in part, to our findings. 
More cell biological experiments dedicated to radiotracer affinity and uptake kinetics in cells expressing mouse 
or human NIS variants are required to elucidate this and are subject of future work.
Thirdly, we observed that [18F]BF4− is cleared faster and more completely from the blood than [123I]iodide 
(Fig. 4c). [123I]iodide is incorporated into hormones within the thyroid 7 and it is not unlikely that a certain por-
tion of these hormones is secreted back into circulation31, 32, thereby contributing to lower apparent clearance of 
123I from the blood stream. It may be that [18F]BF4− is more efficiently extracted and excreted by the kidneys than 
[123I]iodide, but more studies will be required to distinguish the precise mechanistic reasons for these apparent 
differences in clearance rates. Regardless of the mechanism, the faster and more complete blood clearance con-
tributes to higher target-to-background ratios in non-thyroidal NIS expressing tissues for [18F]BF4− than for [123I]
iodide (18- to 30-fold better tumor-to-blood pool surrogate in the case of [18F]BF4− depending on the imaging 
time after tracer administration).
[18F]BF4− uptake in NIS expressing organs and lesions stemming from our NIS reporter gene-expressing 
breast cancer cells was specific and confirmed ex vivo by radioactivity measurements in individual tissues (Figs 2 
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Figure 6. Metastasis detection with [18F]BF4−-PET is superior to metabolic imaging by [18F]FDG-PET in 
the NIS-expressing tumor model. 3E.Δ-NIS tumors were established and grown to sizes of ~350 mm3 before 
being imaged (see Materials and Methods). (a, left) Animals were first imaged by [18F]BF4−-PET. A maximum 
intensity projection (overlaid on CT) is shown. Abbreviations are: bladder (B), stomach (S), thyroid and 
salivary glands (Th + SG), and primary tumor (T); open arrow). Full arrows point to metastatic sites, which 
include the following objects in this animal (from left to right and top to bottom): right axillary LN, left axillary 
LN, left inguinal LN (draining LN of the primary tumor). (a, right) The animals were allowed to recover after 
imaging and the radioactivity was allowed to decay (48 h) before metabolic imaging with [18F]FDG-PET was 
performed on the same animals. A maximum intensity projection (overlaid on CT) of the same animal as in (a) 
is shown. Abbreviations are: bladder (B), heart (H), kidneys (K), and primary tumor (T; open arrow). Signal-to-
background is insufficient to identify any of the metastatic sites previously identified in (a, left). (b) [18F]FDG 
biodistribution data expressed as SUV as determined by γ-counting post tissue harvesting. Abbreviations are 
(from left to right): primary tumors (T), axillary lymph nodes (cancer positive; ALN), inguinal lymph nodes 
(cancer cell positive; ILN), metastasis-free lymph nodes (-veLN), liver metastases (LM), peritoneal metastases 
(PM), heart (H), blood (BL), muscle (Mu), bone (whole femur; Bo), thyroid and salivary glands combined 
(Th + SG), and stomach (S). Shown are pooled data (N = 8 animals) and error bars represent SEM. While lymph 
node metastasis could not be identified by imaging (a, right), ex vivo γ-counting allowed the differentiation 
of LNs that contained cancer cells (ALN, ILN) from metastasis-free LNs (-veLN), albeit with a small dynamic 
range. Liver (LM) and peritoneal (PM) metastases were not distinguishable from metastasis-free organs by ex 
vivo γ-counting.
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and 5). In vivo, [18F]BF4− enabled detection of primary tumors but, importantly, also small metastatic lesions. [18F]
BF4−-PET-positive lesions were analyzed by immunofluorescence microscopy for cancer cell presence, which was 
confirmed in all cases (N = 20 different metastatic tissues from eight different animals; Fig. 5). Lymph nodes were 
the expected sites of metastasis in this model; all lymph nodes found to be positive by imaging contained cancer 
cells and vice versa, all lymph nodes in which we found cancer cells were also detected by imaging that preceded 
tissue harvesting and histology. We also analyzed [18F]BF4−-PET-negative lymph nodes using ex vivo immunoflu-
orescence microscopy and did not find any cancer cells in those tissues (N = 17 different metastasis-free axillary 
and inguinal lymph nodes from eight animals; Fig. 5). These findings were in agreement with our previous study 
establishing NIS reporter gene imaging as an excellent strategy for in vivo metastasis tracking by SPECT imaging 
using 99mTcO4−. The sensitivity of our [18F]BF4−-PET imaging approach in vitro was ~2000 NIS-expressing cells 
in a volume of 0.5 million NIS-negative cells (Supplementary Fig. S1) and also comparable to our previous [99mTc]
pertechnetate-SPECT experiments28.
We were further interested in comparing this [18F]BF4−-PET imaging approach to routine metabolic imaging 
by [18F]FDG-PET in our NIS expressing tumor model. We found the SUV values for [18F]BF4− to be signifi-
cantly larger as compared to those obtained by use of [18F]FDG in the same organs (compare Figs 5g with 6b). 
Importantly, metastasis detection by PET imaging could not be achieved with [18F]FDG-PET due to the short-
comings of [18F]FDG with respect to its contrast and specificity; other organs with high metabolic activities such 
as the heart and kidneys led to a deterioration of contrast in adjacent organs of interest such as the lung and 
lymph nodes. [18F]FDG heart uptake can, however, be suppressed (but not abolished) by fasting the animals prior 
to the administration of [18F]FDG33. While metabolic imaging by [18F]FDG-PET is more versatile in preclinical 
research in that it does not require tumor models genetically engineered to express a reporter gene such as NIS, it 
is of very limited use for metastasis imaging and longitudinal metastasis tracking and related drug and treatment 
development studies. In contrast, we demonstrated sensitive and specific metastasis detection by [18F]BF4−-PET 
imaging in a NIS-expressing tumor model.
In vivo cell tracking is currently a growing field, enabled by technological advances that improved detection 
limits, resolution and accessible information through multiplexing (enabled by multi-modality imaging). In this 
study, we apply this concept to track spontaneous cancer cell metastasis, also with a view to using this as an assay 
for the evaluation and validation of future anti-metastatic drug candidates. Importantly, our reporter gene:radio-
tracer pair for PET imaging (NIS:F-18-tetrafluoroborate) can also be used for different cell tracking applications. 
For example, cell therapies are currently emerging as promising therapeutic approaches not only for the treatment 
of cancer34 but also in the contexts of transplantation immunology35 and regenerative medicine36, 37. Whole-body 
in vivo imaging-afforded cell tracking applications are becoming increasingly important for the successful devel-
opment and translation of such cell therapies, in particular in the contexts of therapy safety and monitoring.
Conclusion
We successfully demonstrated the utility of the recently developed NIS radiotracer [18F]BF4− for tumor and metas-
tasis imaging by PET in a preclinical model of breast cancer. We demonstrated very high sensitivity and specificity 
of the approach and also provided an explanation as to why the pharmacokinetic properties of [18F]BF4− are 
better suited for studying NIS-expressing tumor models than those of radioiodine. In addition, we demonstrated 
that the detectability of NIS-expressing cancer cells and consequently metastasis tracking is greatly enhanced 
when [18F]BF4−-PET is used as NIS tracer as compared to routine metabolic imaging afforded by [18F]FDG-PET. 
This will be particularly useful for challenging applications in cancer research (e.g. response-to-treatment studies, 
development of anti-metastatic therapies etc.). In addition, we believe that other fields in need of highly sensitive 
in vivo cell tracking tools are likely to benefit from this methodology (e.g. immunology and stem cell research).
Materials and Methods
Reagents and Cells. All chemicals and reagents were purchased from Fischer-Scientific (Loughborough, 
UK), Millipore (Watford, UK), Sigma (Gillingham, UK) or VWR (Lutterworth, UK) unless otherwise indicated. 
Fisher rat thyroid cells FRTL-5 were purchased from ATCC (via LGC Standards, Teddington, UK). Rat breast 
adenocarcinoma cells (MTLn3E) were a gift from Dr. Erik Sahai (London Research Institute) and were engi-
neered to express the truncated version of the chemokine CXC receptor 4 (Δ34-CXCR4) fused to monomeric 
eGFP (cells named 3E.Δ) to obtain a highly metastatic cancer cell line26 that spontaneously metastasizes. These 
cells were further modified to stably express human NIS fused to monomeric TagRFP (cells named 3E.Δ-NIS) 
and NIS expression and function was confirmed previously28. For cell culture see Supplementary Information. 
[123I]iodide was purchased from GE Healthcare (Little Chalfont, UK). [18F]BF4− was synthesized as previously 
described with minor modifications23 (see Supplementary Information).
Cellular uptake of NIS tracers. Uptake experiments were performed as previously described28, but with 
[18F]BF4− as a radiotracer (50 kBq per mL per 106 cells). Uptake in the cells was compared to TSH-stimulated 
the FRTL-5 cells. For the comparison of relative tetrafluoroborate and iodide uptake into cells, we performed 
competition assays against [99mTc]pertechnetate. Briefly, standard uptake assays (as previously described28) were 
performed in the presence of differing amounts of either cold tetrafluoroborate, cold iodide or [99Tc]pertechnetate 
(for assay details see Supplementary Fig. 3). The co-substrate effects on cellular [99mTc]pertechnetate uptake were 
quantified and fitted to a sigmoid model using Prism software v7.01 (GraphPad, La Jolla, US).
Animal tumor model. Young adult (5–6 weeks old) female SCID/Beige (CB17.Cg-PrkdcscidLystbg−J/Crl; 
Charles River, UK) were a kind gift of Dr. Maher (King’s College London). All animals were housed within 
filter-top cages in Scantainer units in approved facilities and given food and water ad libitum. 3E.Δ.NIS cells were 
trypsinized, washed with pre-warmed Hank’s buffered saline (HBSS; without Ca2+ and Mg2+), re-suspended, 
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counted, and aliquots of 5 × 105 cells in 50 µL HBSS were injected subcutaneously into the left mammary fat pad 
between nipples four and five. Once palpable, tumor volumes were measured with calipers using the following 
formula; V = π/6·l·w·d, where l is length, w is width and d is depth. All animal experiments were approved by the 
UK Home Office and an ethical review panel and all requirements dictated by E.U. and UK legislation and the 
above committees were met.
In vivo radionuclide imaging. Mice were anesthetized using isoflurane (2% (v/v) in O2) and radiotracers 
were injected into their tail veins; 5 MBq of [18F]BF4− or [18F]FDG, or 15 MBq of [123I]iodide, each in 100 μL 
HBSS. In static scans, animals were sedated and imaged 40 min after radiotracer administration using nanoS-
canPET/CT (Mediso, Budapest, Hungary) or nanoSPECT/CT Plus (Mediso, Budapest, Hungary) instruments. 
Static PET and SPECT scans lasted 30 min each with CT image acquisition performed subsequent to radionuclide 
imaging. In dynamic scans, PET/CT acquisition was started before radiotracer administration and animals were 
imaged from the moment of radiotracer administration for 2 h. To make dynamic PET/CT data comparable to 
static SPECT/CT data, dynamic PET/CT data were binned into 12 min time intervals, and thereby rendered 
static to match the static time-series of the SPECT/CT data. PET imagereconstruction was performed using 
Tera-TomoTM 3D PET image reconstruction software (Mediso, Budapest, Hungary). SPECT/CT scans were per-
formed sequentially for 12 min each and individually reconstructed over a period of 2 h. Decay correction for the 
different radioisotope half lives was done using the built-in features in the analysis software packages.
For specificity tests of the NIS radiotracer [18F]BF4−, animals were first imaged and then rested awake until the 
radioactivity had decayed sufficiently to be regarded as negligible, i.e. 48 h (1.3 · 10−6% residual 18F radioactivity). 
Subsequently, the competitive substrate perchlorate was administered at a dose of 200 mg/kg and 30 min later ani-
mals were re-imaged under the same conditions as described above. Importantly, repeat imaging with the same 
radiotracer was no affected by tracer amounts from the first imaging session (Fig. S3).
Analysis of radioactivity from images and in harvested tissues. To quantify the radioactivity from 
images, 3D volumes of interest (VOI) enclosing the tumor, other organs of interest, or the whole mouse excluding 
the tail were drawn. The total activity in the whole animal (excluding the tail) at t = 0 was defined as the injected 
dose. Radioactivity in each VOI at each time point was measured and expressed as percent of injected dose (%ID). 
Each radiotracer time-activity curve (TAC) was an average of %ID of three xenograft-bearing animals. CT images 
were used to draw a VOI and provide the volumes required for SUV calculations from imaging data. A volume 
comprising of the left ventricle of the heart served as a surrogate for the blood pool with the procedure for obtain-
ing corresponding TACs being described elsewhere38.
In metastases detection experiments the same animals were imaged via PET/CT with [18F]BF4− and with [18F]
FDG on days 17 and 19, respectively. Day 17 [18F]BF4−-PET/CT images were used to identify focal radiotracer 
uptake. Subsequently, tissues were harvested for ex vivo γ-counting ([18F]FDG biodistribution) using a 1282 
Compugamma counter (LKB-Wallac, Australia). For the ex vivo comparison of [18F]BF4− and [18F]FDG biodis-
tributions, additional mice from the same experimental cohort (also imaged by [18F]BF4−-PET on day 17) were 
injected with [18F]BF4− (but not [18F]FDG) on day 19, and tissues harvested and subjected to ex vivo γ-counting 
([18F]BF4− biodistribution).
For terminal ex vivo γ-counting, animals were euthanized one hour following radiotracer administration. 
All harvested tissues were γ-counted and their standardized uptake values (SUVs) calculated as previously 
described28. A minimum of four animals was used for this type of ex vivo analysis per experimental cohort. 
Furthermore, all harvested tissues were subjected to histologic analysis by confocal fluorescence microscopy.
Histologic analysis by confocal fluorescence microscopy. Harvested tissues were embedded in opti-
mal cutting temperature (OCT) medium and frozen in isopentane pre-cooled over liquid nitrogen and stored at 
−80 °C. 10 µm sections were cut with a Cryomatic cryostat (Bright Ltd, Huntingdon, UK), placed on Superfrost 
Plus slides and fixed with paraformaldehyde (1 mg/mL in HBSS) for 15 min at room temperature. Fixed slides 
were stained with Hoechst 33342 (1 µg/mL; Invitrogen, Paisley, UK) for 15 min at room temperature, washed 
with HBSS (3x for 5 min) and rinsed with deionized water before being mounted with Vectashield (Vectorlabs, 
Peterborough, UK). Images were taken with a TCS SP5II confocal fluorescence microscope (Leica, Wetzlar, 
Germany) equipped with a Plan-Apochromat 63x/1.4NA objective and filter sets appropriate for imaging Hoechst 
33342 (cell nuclei), GFP (Δ34-CXCR4-GFP) and TagRFP (NIS-TagRFP). Images were acquired with the LAS-AF 
software, exported in TIFF file format and post-processed using ImageJ software v1.41 (NIH).
Statistical analysis. Two-tailed unpaired Student’s t-tests (with alpha of 0.05) were used for comparisons 
between the two radiotracers. Sample sizes in comparative experiments were equal (unless otherwise indicated). 
Numbers in the text indicate means of pooled data ± standard deviation (SD) unless otherwise stated. All statis-
tical data were calculated using Prism software v7.01 (GraphPad, La Jolla, CA/USA).
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